

Short communication

Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer

J.R. McClanahan^a, R. Peyyala^b, R. Mahajan^b, R.C. Montelaro^c, K.F. Novak^{b,1}, D.A. Puleo^{a,*}^a Center for Biomedical Engineering, University of Kentucky, Lexington, KY, USA^b Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, KY, USA^c Center for Vaccine Research and Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA

ARTICLE INFO

Article history:

Received 16 May 2011

Accepted 22 July 2011

Keywords:

Anti-infectives

Antimicrobial peptide

Periodontitis

Polymeric drug carrier

Streptococcus gordonii

WLBU2

ABSTRACT

WLBU2 is a peptide antibiotic designed for broad antimicrobial activity, including bacteria associated with periodontal disease. Although periodontitis is associated with various systemic conditions, ranging from cardiovascular disease to preterm birth, local therapy is needed to treat the source of infection. Biodegradable polymers are often used to control locally the amount and rate of delivery of drugs. In the present study, a bioerodible association polymer comprising cellulose acetate phthalate (CAP) and Pluronic® F-127 (PF-127) was explored for its interaction with WLBU2. The intrinsic antimicrobial activity of CAP/PF-127 and the combined effects of the polymer and WLBU2 were examined using *Streptococcus gordonii*, a species involved in early colonisation of tooth surfaces. The polymer blend alone had dose-dependent bacteriostatic properties, resulting in a ≥ 2 log decrease in colonies at the highest concentrations tested, possibly due to the hydrophobicity of CAP disrupting the surface of bacteria. When WLBU2 was combined with CAP/PF-127, an apparent binding of peptide to polymer significantly decreased the activity compared with free WLBU2, which functions like other cationic peptides by destabilising the bacterial membrane. Formulation with sucrose as an excipient, which reduced the interaction between WLBU2 and polymer, restored the bactericidal activity of the peptide antibiotic as reflected by a >3 log decrease in *S. gordonii*. WLBU2 can be locally delivered using CAP/PF-127 as a release vehicle, with the peptide's bactericidal activity dominating the polymer's bacteriostatic effect.

© 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

1. Introduction

Bacteria and bacterially derived products stimulate inflammation and lead to the destruction of structural tissues supporting teeth and implants in conditions such as periodontitis and peri-implantitis. Although other bacterial types will also be present, streptococci dominate as early colonisers of tooth surfaces, constituting up to 90% of the bacteria that quickly attach following professional cleaning [1].

Systemic delivery of antibiotics to treat oral infections can cause a number of adverse effects, including foetal toxicity, teratogenesis, discoloration and hyperplasia of teeth, and depressed skeletal growth [2]. Localised delivery, however, can not only reduce side effects but also reduce the amount of drug used. An obstacle to effectively implementing therapeutic use of many biomolecules is development of an appropriate delivery system.

Concerns about the emergence of antibiotic-resistant bacteria necessitate the consideration of alternative treatments. Cationic antimicrobial peptides (AMPs) often have broad antimicrobial activity and can kill or neutralise Gram-negative and Gram-positive bacteria, fungi and parasites [3]. AMPs are natural products in sites likely to encounter pathogens, such as the skin, ears, eyes and various epithelial surfaces. WLBU2 is a 24-amino-acid peptide derived from lentivirus lytic peptide 1 that was designed for broad activity against both Gram-positive and Gram-negative bacteria [4]. More recently, WLBU2 has been shown to be effective against oral bacteria [5]. Cationic amphiphilic peptides function by destabilising the bacterial membrane following electrostatic binding to lipopolysaccharide, after which the peptides can interact with cytoplasmic components [3,4].

In this project, the bioactivity of WLBU2 peptide antibiotic was studied in conjunction with a bioerodible polymer capable of localised drug delivery. In particular, the association polymer blend system of cellulose acetate phthalate (CAP) and Pluronic® F-127 (PF-127) was used because it provides zero-order kinetics and has been shown to be useful for releasing different biomolecules, including small-molecule drugs, peptides and proteins [6,7]. In contrast to most biodegradable materials used for drug delivery, CAP/PF-127 physically erodes following deprotonation of the

* Corresponding author. 209 Wenner-Gren Lab, Center for Biomedical Engineering, University of Kentucky, Lexington, KY 40506-0070, USA. Tel.: +1 859 257 2405; fax: +1 859 257 1856.

E-mail address: puleo@uky.edu (D.A. Puleo).

¹ Present address: American Dental Education Association, Washington, DC, USA.




Fig. 1. Bacteriostatic effect of cellulose acetate phthalate/Pluronic® F-127 (CAP/PF-127) polymer erosion byproducts on (A) *Escherichia coli* and (B) *Streptococcus gordonii*. Statistically significant concentration-dependent effects were seen both for *E. coli* ($P < 0.001$) and for *S. gordonii* ($P < 0.01$). Data are the mean $\pm$ standard deviation ($n = 3$). CFU, colony-forming units.

carboxyl groups of CAP, which disrupts hydrogen bonding with the ether oxygens of PF-127.

2. Materials and methods

2.1. Microsphere fabrication and degradation

CAP/PF-127 microspheres were made by a water–acetone–oil–water triple emulsion process as reported elsewhere [6,7]. A 70:30 (w/w) CAP:PF-127 blend ratio was used because it degrades by surface erosion under a variety of conditions. Microspheres were sterilised with ultraviolet radiation in a laminar flow hood for 30 min. CAP/PF-127 degradation products (1.5 mg/mL) were obtained by eroding polymer in 150 mM phosphate-buffered saline (pH 7.4) during incubation at 37 °C.

2.2. Antimicrobial activity

The antibacterial effects of CAP/PF-127 and WLBU2 on *Streptococcus gordonii* (as an important Gram-positive, commensal microorganism responsible for early colonisation of teeth) and *Escherichia coli* (as a positive control) were determined using a standard broth dilution assay as described previously [5]. In brief, bacteria were propagated to mid-log phase, washed with 10 mM phosphate buffer (PB) and re-suspended in PB to achieve an initial

density of 10^6 to 10^7 colony-forming units/mL in the killing assay. Bacterial cultures were incubated at 37 °C with twofold dilutions of CAP/PF-127 degradation products or WLBU2 peptide under appropriate growth conditions for 30 min. This time was selected because it exceeds the minimum time needed for WLBU2 to kill in serum, which is analogous to the subgingival transudate. Survival of bacteria was measured by plating 10-fold serial dilutions of the treated suspensions on blood agar and counting colonies after incubating for 24 h.

2.3. Statistical analysis

Results (mean $\pm$ standard deviation) were calculated from triplicate samples. Following one-way analysis of variance (ANOVA), post hoc comparisons were made using the Tukey–Kramer test when the P -value was significant ($P < 0.05$).

3. Results and discussion

3.1. Effects of CAP/PF-127 polymer on *Escherichia coli* and *Streptococcus gordonii*

As shown in Fig. 1, even in the absence of an antimicrobial agent, CAP/PF-127 resulted in a statistically significant, concentration-dependent inhibition both of *E. coli* ($P < 0.001$) and *S. gordonii* ($P < 0.01$). The overall magnitude of the effect as well as the sensitivity differed for the two types of bacteria. For *E. coli*, the number of colonies was nearly 1000 times lower than in control cultures at 3.125% (47 μ g/mL) polymer degradation products or higher. Even at the lowest concentration tested (1.56%), growth was still reduced more than 10-fold compared to controls. *S. gordonii* was less sensitive to the polymer, with a 2.5 log reduction observed at only the highest (100%; 1.5 mg/mL) concentration; a reduction of less than one order of magnitude was observed at the lowest concentration of polymer tested. Micronised CAP formulated into a cream, however, has been reported to have microbicidal properties, including blocking human immunodeficiency virus type 1 (HIV-1) and herpes virus infectivity as well as activity against bacteria associated with vaginosis [8,9]. Although the mechanism of bacteriostatic activity of CAP and/or PF-127 in these studies is unknown, two possibilities are described in the literature [8,9]. First, micronised CAP has been associated with reduced environmental pH, but the buffered




Fig. 2. Bactericidal effect of WLBU2 peptide on *Escherichia coli* and *Streptococcus gordonii*. Results are shown only for concentrations that caused a ≥ 3 log reduction. The peptide was effective against *E. coli* at significantly lower concentrations ($P < 0.001$) than it was against *S. gordonii*. Data are the mean $\pm$ standard deviation ($n = 3$). CFU, colony-forming units.

Download English Version:

<https://daneshyari.com/en/article/3359367>

Download Persian Version:

<https://daneshyari.com/article/3359367>

[Daneshyari.com](https://daneshyari.com)